Patent classifications
C07C217/84
2,2' -DIAMINOBIARYLS HAVING ONE PRIMARY AND ONE SECONDARY AMINE
Novel 2,2′-diaminobiaryls having one primary and one secondary amine and an electrochemical process for preparation thereof.
2,2' -DIAMINOBIARYLS HAVING ONE PRIMARY AND ONE SECONDARY AMINE
Novel 2,2′-diaminobiaryls having one primary and one secondary amine and an electrochemical process for preparation thereof.
POLYMORPHIC FORMS OF RAD1901-2HCL
Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.
POLYMORPHIC FORMS OF RAD1901-2HCL
Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.
PROCESS FOR PREPARING SUBSTITUTED ANILINES
The present invention relates to a process for preparing compounds of the formula (I)
##STR00001##
starting from compounds of the formula (II)
##STR00002##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.3′ are defined in according to the invention.
PROCESS FOR PREPARING SUBSTITUTED ANILINES
The present invention relates to a process for preparing compounds of the formula (I)
##STR00001##
starting from compounds of the formula (II)
##STR00002##
wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.3′ are defined in according to the invention.
EBNA1 inhibitors and their method of use
Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
EBNA1 inhibitors and their method of use
Pharmaceutical compositions of the invention comprise EBNA1 inhibitors useful for the treatment of diseases caused by EBNA1 activity such as cancer, infectious mononucleosis, chronic fatigue syndrome, multiple sclerosis, systemic lupus erythematosus and rheumatoid arthritis. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by latent Epstein-Barr Virus (EBV) infection. Pharmaceutical compositions of the invention also comprise EBNA1 inhibitors useful for the treatment of diseases caused by lytic Epstein-Barr Virus (EBV) infection.
Method for producing optically active compound, and novel metal-diamine complex
The present invention pertains to a method for producing an optically active compound which includes a step for reducing an imino group of an imine compound or a step for reducing an unsaturated bond of a heterocyclic compound, while in the presence of hydrogen gas as a hydrogen donor and one or more types of complexes selected from a group consisting of a complex represented by general formula (1), a complex represented by general formula (2), a complex represented by general formula (3), and a complex represented by general formula (4) (the general formulas (1)-(4) are as stipulated by claim 1).
Method for producing optically active compound, and novel metal-diamine complex
The present invention pertains to a method for producing an optically active compound which includes a step for reducing an imino group of an imine compound or a step for reducing an unsaturated bond of a heterocyclic compound, while in the presence of hydrogen gas as a hydrogen donor and one or more types of complexes selected from a group consisting of a complex represented by general formula (1), a complex represented by general formula (2), a complex represented by general formula (3), and a complex represented by general formula (4) (the general formulas (1)-(4) are as stipulated by claim 1).